A
Alcista
Alcista · 25%COO
$100.88
Precio del escenario
$57.940
+0.545 (+0.94%)Al cierre
Loading chart…
- Máximo
- 58.250
- Apertura
- 58.000
- Precio medio ponderado por volumen
- 57.85
- Volumen
- 3.77M
- Capitalización
- 17.45B
- Mínimo
- 57.370
- Importe
- 218.31M
- EV/EBITDA, TTM
- 10.22
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.
Análisis de IA of Cooper Companies Inc (COO)
ComprarCooper Companies Inc is a good buy right now due to its recent performance and insider confidence. The current price is $57.94, and the RSI is at 70.129, indicating strong momentum. Additionally, the forward P/E ratio is 11.34, suggesting the stock is undervalued compared to its earnings potential. However, there is a risk of a potential decline in revenue growth, with expectations of only 0% to 2% growth for the fourth quarter.
Recomendaciones de analistas (15)
+55.90% de potencial alcista
Comprar
10 Comprar
5 Mantener
0 Vender
Actual: 57.94
Mínimo
73.00
Promedio
90.33
Máximo
100.00
Barclays
Equal Weight
$60
2026-10-06
Barclays
2026-10-06
Precio objetivo
$60
Equal Weight
Mizuho
Superar al mercado
$75
2026-09-11
Mizuho
2026-09-11
Precio objetivo
$75
Superar al mercado
JPMorgan
Neutral
$58
2026-09-10
JPMorgan
2026-09-10
Precio objetivo
$58
Neutral
Needham
Comprar
$73
2026-09-10
Needham
2026-09-10
Precio objetivo
$73
Comprar
Citi
Neutral
$60
2026-09-10
Citi
2026-09-10
Precio objetivo
$60
Neutral
Métricas de valoración
El PER previsto actual de Cooper Companies Inc (COO) es 11.34, frente a su media de 5 años de 22.84.
Escenarios de precio de Alphio AI para COO
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con COO en cartera
Cronología de eventos
Noticias
7.010-13PRnewswireRosen Law Firm Investigates Securities Claims Against The Cooper Companies
5.010-07FoolKurzius Increases Stake in Cooper Companies
5.010-07FoolDirector Paul A. Keel Acquires $250,000 in Cooper Companies Shares
5.010-06FoolCooper Companies Director Increases Stock Holdings
7.010-05PRnewswireRosen Law Firm Investigates Securities Claims Against Cooper Companies
Preguntas frecuentes sobre COO, respondidas por Alphio AI
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).
Cooper Companies Inc is a good buy right now due to its recent performance and insider confidence. The current price is $57.94, and the RSI is at 70.129, indicating strong momentum. Additionally, the forward P/E ratio is 11.34, suggesting the stock is undervalued compared to its earnings potential. However, there is a risk of a potential decline in revenue growth, with expectations of only 0% to 2% growth for the fourth quarter.
15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.